Corcept Therapeutics president Vieira sells $29,842 of stock

Corcept Therapeutics' President Roberto Vieira sold 296 shares of the company's stock on September 16, 2026. Each share was sold for $100.82, resulting in a total of $29,842. The stock has increased by 224% over the past six months, driven by improving fundamentals. This transaction was part of a pre-planned 10b5-1 trading plan Vieira adopted in June 2026.

After this sale, he still owns 3,946 shares, including shares from unvested restricted stock awards that are set to vest in a year, provided he meets certain requirements. Despite some analysts suggesting the stock is overvalued, the company has a "GOOD" financial health score. Recently, Corcept Therapeutics reported strong second-quarter 2026 earnings, with revenue up 32% year-over-year.

The company has also raised its revenue outlook for the year. Analysts have raised their price targets for the stock, reflecting continued growth in their core business.